Zandelisib (ME-401) in Japanese patients with relapsed or refractory indolent non-Hodgkin’s lymphoma: an open-label, multicenter, dose-escalation phase 1 study

The selective phosphatidylinositol 3-kinase δ inhibitor zandelisib demonstrated favorable safety and efficacy [objective response rate (ORR) 79%] in patients with B-cell malignancies in a phase 1b study in the US and Switzerland. In this phase 1 dose-escalation study (NCT03985189), 9 Japanese patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Goto, Hideki, Izutsu, Koji, Ennishi, Daisuke, Mishima, Yuko, Makita, Shinichi, Kato, Koji, Hanaya, Miyoko, Hirano, Satoshi, Narushima, Kazuya, Teshima, Takanori, Nagai, Hirokazu, Ishizawa, Kenichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668928/
https://www.ncbi.nlm.nih.gov/pubmed/36107394
http://dx.doi.org/10.1007/s12185-022-03450-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668928/
https://www.ncbi.nlm.nih.gov/pubmed/36107394
http://dx.doi.org/10.1007/s12185-022-03450-5

Ejemplares similares